atezolizumab

targets

all catalysts(41)

News(9)

• BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
  Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The news follows Merck and Moderna’s Phase…
  biospace · 6d ago
• Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
  Fresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ivonescimab’s ability beyond non-small cell lung cancer, even as she con…
  fiercebiotech · 8d ago
• Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
  Summit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…
  biospace · 1mo ago
• Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
  Roche may have scrapped work on a T-cell engager being evaluated for lupus, but the company’s head of pharma told Fierce that still has a strategy for developing cell therapies for autoimmune disea…
  fiercebiotech · 1mo ago
• Design Therapeutics' Friedreich's ataxia data; Vincentage's obesity results from China
  Plus, news about Enhertu and Tecentriq. 💪 Design Therapeutics shares Phase 1/2 data in Friedreich's ataxia: The California biotech’s DT-216P2 given at 1 mg/kg led to an average 6.4-point improveme…
  endpoints · 3mo ago
• Dr Hafron on the FDA Approval of Adjuvant Atezolizumab in MRD+ MIBC
  Jason Hafron, MD, discusses the significance of the FDA approval of adjuvant atezolizumab for MRD+ muscle-invasive bladder cancer.
  onclive · 3mo ago
• FDA Approves Adjuvant Atezolizumab for MRD+ Muscle-Invasive Bladder Cancer
  The FDA approved adjuvant atezolizumab for muscle-invasive bladder cancer with circulating tumor DNA molecular residual disease.
  onclive · 3mo ago
• Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
  Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.
  onclive · 3mo ago
• Simlukafusp Alfa Regimens Show Manageable Safety and Activity But Do Not Outperform SOC in Metastatic RCC
  Simlukafusp alfa plus atezolizumab with/without bevacizumab was safe and active but did not improve upon responses with SOC treatments in metastatic RCC.
  onclive · 4mo ago